Insmed Incorporated INSM
Set alert
104.74 USD -4.57 -4.18%
As of Nov 3, 11:54 AM ET
104.32 Day range 111.11
91.88 52-week range 211.41
- YTD
- -39.82%
- 1 year
- -43.76%
- Open
- 108.70
- Prev close
- 109.31
- Mkt cap
- 22.95B
- Vol
- 1.37M
- Avg vol
- 2.93M
- EPS
- -2.81
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 104.32
- High
- 111.11
- Forward P/E
- 146.52
- Beta
- 0.81
- Short ratio
- 4.85
- Inst. own
- 105.49%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 18, 2027
- 50-d avg
- 112.66
- 200-d avg
- 125.42
- 1y target
- 193.95
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 193.95 +85.2% upside
Now 104.74
- Target (low)
- 154.00
- Target (mean)
- 193.95
- Target (high)
- 243.00
Ratings (0m) 24 23 buy · 1 hold · 0 sell
- Strong buy5
- Buy18
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 24
- 1 month ago 24
- 2 months ago 23
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.35311 | -0.89 – -0.02024 | -1.54 | +77.1% | 597.94M | +126.6% | 15 |
| Next quarter | -0.21667 | -0.53 – 0.07 | -0.76 | +71.5% | 626.51M | +104.8% | 6 |
| Current year | -1.80 | -2.28 – -1.31 | -6.42 | +71.9% | 1.86B | +206.3% | 14 |
| Next year | 0.58722 | -0.82 – 2.02 | -1.80 | +132.6% | 2.98B | +60.5% | 16 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | Guggenheim | Maintained | Buy | Buy |
| Oct 21, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Oct 12, 2026 | Wolfe Research | Downgrade | Outperform | Peer Perform |
| Oct 12, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 30, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 15, 2026 | Roth Capital | Reiterated | Buy | Buy |
| Aug 10, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 10, 2026 | Truist Securities | Reiterated | Buy | Buy |
| Aug 7, 2026 | Guggenheim | Maintained | Buy | Buy |
| Aug 7, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 7, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Jul 21, 2026 | BMO Capital | Initiated | — | Outperform |
| Jul 15, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Jul 10, 2026 | Guggenheim | Reiterated | Buy | Buy |
| Jun 22, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Jun 8, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Jun 5, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| May 14, 2026 | Truist Securities | Maintained | Buy | Buy |
| May 8, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| May 8, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| May 8, 2026 | Guggenheim | Maintained | Buy | Buy |
| Apr 17, 2026 | Roth Capital | Reiterated | Buy | Buy |
| Apr 14, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Apr 1, 2026 | Barclays | Maintained | Overweight | Overweight |
| Mar 30, 2026 | Morgan Stanley | Upgrade | Equal-Weight | Overweight |
| Mar 26, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 25, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Mar 24, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Mar 24, 2026 | Stifel | Maintained | Buy | Buy |
| Mar 24, 2026 | Wells Fargo | Maintained | Overweight | Overweight |